Question: Bracketed Stability studies…What are they and can they be used in compounding for stability studies? (Part II)
Answer:
Last week, we presented information about a very simple bracketed stability study that involved only two variables (strength and batch number). This week, we will present a table for a bracketed stability study that is somewhat more complex, which includes a third variable (in this example, package size).
Three Strengths: (50 mg, 75 mg, and 100 mg)
Three Package Sizes: (15 mL, 100 mL, and 150 mL)
Three Batches of Each Strength: (B)
Strength | 50 mg | 75 mg | 100 mg |
Batch (B) | B1 | B2 | B3 | B1 | B2 | B3 | B1 | B2 | B3 |
Package Size |
50 mL | T | T | T | – | – | – | T | T | T |
100 mL | – | – | – | – | – | – | – | – | – |
150 mL | T | T | T | – | – | – | T | T | T |
“T� = Tested; “–� = Not Tested
The rationale for bracketing can include the following:
1. Interpolation between extremes is logical.
2. There is no need for the stability to be the same.
3. Savings (e.g., personnel, time, testing).
The issues against bracketing include the following:
1. Some preparations/products and their packaging may be dropped.
2. There is a potential for additions outside of the “bracket.�
Concerning “bracketing,� what is justified and what is not? Below is a brief summary:
- Strengths of identical or closely related formulations can be bracketed without further justification.
- Relative amounts of drug substances and excipient changes in a formulation can be bracketed with justification.
However, one cannot use bracketing with different excipients with different strengths.
Continued next week
REMINDER: For those State Boards of Pharmacy that are not adopting the USP chapters and are preparing their own or using their own modifications of the chapters, easily-modifiable alternative versions of Chapters <795>, <797>, and <800> have been prepared and are available as a free download for use by state boards of pharmacy to modify for their individual states at the following website.
CompoundingToday.com
Pharmacists may wish to download and send to your state board of pharmacy for consideration.
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition
Did you know that the new USP <797> BUD standards not allowing extended stability will effectively eliminate the usefulness of ALL published and nonpublished stability studies for BUDS in:
Trissel’s Handbook of Injectable Drugs
King Guide to Parenteral Admixtures
CompoundingToday.com
International Journal of Pharmaceutical Compounding
American Journal of Health-System Pharmacists
Annals of Pharmacotherapy
Pharmaceutical science journals containing stability studies:
Journal of Pharmaceutical Sciences
AAPS Pharmaceutical Sciences
International Journal of Pharmaceutics
Many others
Pharmaceutical compounding supply companies and pharmaceutical companies (PHARMA) that have funded and conducted hundreds of stability studies utilizing their drug substances and vehicles.
In summary, the monetary value is in the millions of dollars of data that will now be USELESS!
This poses a financial hardship on all those involved for no valid, justifiable, scientifically-based reason.
Note: A Sterile Compounding Consensus Statement representing a digest of important changes found in the recently published final version of USP Chapter <797> has just been released, and is available on the Compounding Today website at: CompoundingToday.com
All sterile compounders and their allies are encouraged to download and read this concise summary, which includes a number of candid critiques concerning the chapter. Readers are also encouraged to share it or the link to it far and wide – including with their state boards of pharmacy and various organizations.
As USP must rely upon state boards of pharmacy for enforcement of <797>, perhaps these entities can be persuaded to refrain from doing so regarding some more controversial elements of the chapter.
Sterile Compounding Consensus Group (SCCG)
|
|